Stroke, Vol 11, 4-9, Copyright © 1980 by American Heart Association
JE Olsson, C Brechter, H Backlund, H Krook, R Muller, E Nitelius, O Olsson and A Tornberg
156 patients with transient ischemic attacks (TIA) or reversible ischemic
neurological deficit (RIND) were given prophylactic anticoagulant (AC)
treatment against cerebral infarction in a prospective multicenter study
from 5 hospitals in southern Sweden. After 2 months of AC treatment, 135
patients remained in the study and were randomized into 2 groups; one
continued with AC treatment and one changed to anti-platelet therapy. The
patients were followed for 12 months. No significant difference was seen
between the 2 groups but 3 completed cerebral infarctions occurred during
anti-platelet therapy against one during AC treatment. One cerebral
hemorrhage was seen during AC treatment. All completed strokes occurred in
men who initially had carotid symptoms. The number of patients with
TIA/RIND was somewhat higher in the anti-platelet group whereas myocardial
infarctions occurred more often during AC treatment. Compared to the
natural history of untreated TIA/RIND both treatments were found to have a
prophylactic effect against cerebral infarction.
ARTICLES
Anticoagulant vs anti-platelet therapy as prophylactic against cerebral infarction in transient ischemic attacks
This article has been cited by other articles:
 |
|
 |
|
  M. J. O'Donnell, G. J. Hankey, and J. W. Eikelboom Antiplatelet Therapy for Secondary Prevention of Noncardioembolic Ischemic Stroke: A Critical Review Stroke, May 1, 2008; 39(5): 1638 - 1646. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E Schachter, H. A Tran, and S. S Anand Oral anticoagulants and non-cardioembolic stroke prevention Vascular Medicine, February 1, 2008; 13(1): 55 - 62. [Abstract] [PDF]
|
|
|
|
 |
|
 C. J. Glueck, K. Golnik, and Ping Wang Amaurosis Fugax Caused by Heritable Thrombophilia-Hypofibrinolysis in Cases Without Carotid Atherosclerosis: Thromboprophylaxis Prevents Subsequent Transient Monocular Partial Blindness Clinical and Applied Thrombosis/Hemostasis, April 1, 2007; 13(2): 124 - 129. [Abstract] [PDF]
|
|
|
|
|
|
E. Touze, O. Varenne, G. Chatellier, S. Peyrard, P. M. Rothwell, and J.-L. Mas Risk of Myocardial Infarction and Vascular Death After Transient Ischemic Attack and Ischemic Stroke: A Systematic Review and Meta-Analysis Stroke, December 1, 2005; 36(12): 2748 - 2755. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Glueck, N. Goldenberg, H. Bell, K. Golnik, and P. Wang Amaurosis Fugax: Associations with Heritable Thrombophilia Clinical and Applied Thrombosis/Hemostasis, July 1, 2005; 11(3): 235 - 241. [Abstract] [PDF]
|
|
|
|
 |
|
 M. N. Levine, G. Raskob, R. J. Beyth, C. Kearon, and S. Schulman Hemorrhagic Complications of Anticoagulant Treatment: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 287S - 310S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Flossmann and P. M. Rothwell Prognosis of vertebrobasilar transient ischaemic attack and minor stroke Brain, September 1, 2003; 126(9): 1940 - 1954. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Algra, E.L.L.M. De Schryver, J. van Gijn, L.J. Kappelle, and P.J. Koudstaal Oral Anticoagulants Versus Antiplatelet Therapy for Preventing Further Vascular Events After Transient Ischemic Attack or Minor Stroke of Presumed Arterial Origin Stroke, January 1, 2003; 34(1): 234 - 235. [Full Text] [PDF]
|
|
|
|
|
|
M. N. Levine, G. Raskob, S. Landefeld, and C. Kearon Hemorrhagic Complications of Anticoagulant Treatment Chest, January 1, 2001; 119(1_suppl): 108S - 121S. [Full Text] [PDF]
|
|
|
|
 |
|
 C. R. Gomez, S. Cruz-Flores, M. D. Malkoff, C. M. Sauer, and C. M. Burch Isolated vertigo as a manifestation of vertebrobasilar ischemia Neurology, July 1, 1996; 47(1): 94 - 97. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Toni, M. Fiorelli, S. Bastianello, M. L. Sacchetti, G. Sette, C. Argentino, E. Montinaro, and L. Bozzao Hemorrhagic transformation of brain infarct: Predictability in the first 5 hours from stroke onset and influence on clinical outcome Neurology, February 1, 1996; 46(2): 341 - 345. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Maruyama, S. Uchiyama, H. Tohgi, S. Hirai, Y. Ikeda, Y. Shinohara, T. Matsuda, M. Fujishima, and M. Kameyama A Randomized Trial of E5510 versus Aspirin in Patients with Transient Ischemic Attacks: The Japanese E5510 TIA Study-1 (JETS-1) Group Angiology, November 1, 1995; 46(11): 999 - 1008. [Abstract] [PDF]
|
|
|
|
|
|
M.I. Chimowitz, J. Kokkinos, J. Strong, M. B. Brown, S. R. Levine, S. Silliman, M. S. Pessin, E. Weichel, C. A. Sila, A. J. Furlan, et al. The Warfarin-Aspirin Symptomatic Intracranial Disease Study Neurology, August 1, 1995; 45(8): 1488 - 1493. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. G. Hart, B. S. Boop, and D. C. Anderson Oral Anticoagulants and Intracranial Hemorrhage : Facts and Hypotheses Stroke, August 1, 1995; 26(8): 1471 - 1477. [Abstract] [Full Text]
|
|
|
|
 |
|
 Antiplatelet Trialists Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients BMJ, January 8, 1994; 308(6921): 81 - 106. [Abstract] [Full Text]
|
|